|
Jul 22
|
FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink
|
|
Jul 17
|
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)
|
|
Jul 16
|
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)
|
|
Jul 16
|
New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public
|
|
Jul 15
|
Health Canada extends Evkeeza approval for children with HoFH
|
|
Jul 14
|
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection
|
|
Jul 14
|
Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
|
|
Jul 14
|
FDA rejects Ultragenyx gene therapy over manufacturing concerns
|
|
Jul 14
|
Ultragenyx receives complete response letter for UX111 BLA
|
|
Jul 13
|
Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light
|
|
Jun 27
|
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
|
|
Apr 14
|
Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential
|
|
Feb 21
|
Exploring Three High Growth Tech Stocks in the United States
|
|
Feb 19
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 18
|
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
|
|
Feb 15
|
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
|
|
Feb 14
|
Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call
|
|
Feb 14
|
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
|
|
Feb 14
|
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
|
|
Feb 13
|
Ultragenyx: Q4 Earnings Snapshot
|